Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bluejeans who wrote (28657)	4/6/1999 12:48:00 PM
From: RXGOLF	Read Replies (2) \| Respond to of 32384

Good Morning Bob, I have been wanting to post for the last 30 minutes, but Jump Start 3rd Grade was stuck in my CD-ROM and causing all kind of problems. I finally got that rascal out and am back in business. Just goes to show you what kind of problems continuing education can cause<g>. FWIW, the April 1999 Pharmacist Letter had a section on Panretin: "The FDA just approved Panretin(Pan-RET-in, alitretinoin)gel, the first TOPICAL treatment for Kaposi's sarcoma. Alitretinoin is a form of retinoic acid. It's applied to skin lesions to inhibit cell growth...it doesn't prevent new lesions or treat systemic disease. Tell patients to apply Panretin gel BID to QID. Advise them to apply it less frequently if it causes too much skin irritation. You may be shocked at the price...over $2000 for a 60 g tube. Tell patients it actually cost less than other treatments for Kaposi's sarcoma...chemotherapy, radiation, or surgery." Have a great day, Greg